Genetics of ion-channel disorders

Current Opinion in Cardiology

Volumn 27, Issue 3, 2012, Pages 242-252

  Cerrone, Marina ^a   Napolitano, Carlo ^a,b   Priori, Silvia G ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IRCCS   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Brugada syndrome; genetics; ion channels; QT interval; sudden death

Indexed keywords

ANKYRIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CALSEQUESTRIN; CAVEOLIN 3; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; FLECAINIDE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.1; ION CHANNEL; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNE1; POTASSIUM CHANNEL KCNE2; QUINIDINE; RYANODINE RECEPTOR 2; SHAL POTASSIUM CHANNEL; SODIUM CHANNEL; SODIUM CHANNEL NAV1.4; SODIUM CHANNEL NAV1.5; SYNTROPHIN; SYNTROPHIN ALPHA1; UNCLASSIFIED DRUG;

ARRHYTHMOGENESIS; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BRUGADA SYNDROME; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CHANNELOPATHY; ELECTROCARDIOGRAPHY; GAIN OF FUNCTION MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; GENOTYPE; HEART VENTRICLE ARRHYTHMIA; HUMAN; LONG QT SYNDROME; LOSS OF FUNCTION MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SHORT QT SYNDROME;

BRUGADA SYNDROME; CHANNELOPATHIES; GENOTYPE; HUMANS; LONG QT SYNDROME; MYOCYTES, CARDIAC; PHENOTYPE; POTASSIUM CHANNELS; RISK ASSESSMENT; TACHYCARDIA, VENTRICULAR;

EID: 84859913343     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328352429d     Document Type: Review

References (102)

1. Romano C, Gemme G, Pongiglione R. Rare cardiac arrhythmias of the pediatric age II. Syncopal attacks due to paroxysmal ventricular fibrillation (presentation of first case in Italian pediatric literature) (in Italian). Clin Pediatr (Bologna) 1963; 45:656-683.
2. Ward OC. A new familial cardiac syndrome in children. J Ir Med Assoc 1964; 54:103-106.
3. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome: a prospective international study. Circulation 1985; 71:17-21. (Pubitemid 15164757)
4. Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. Circulation 2009; 120:1761-1767.
5. Schwartz PJ, Priori SJ, Napolitano C. The long QT syndrome. In: Zipes D, Jalife J, editors. Cardiac electrophysiology: from cell to bedside. Philadelphia: Saunders Co. 2000. pp. 597-615.
6. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000; 101:616-623. (Pubitemid 30094732)
7. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004; 292:1341-1344. (Pubitemid 39223225)
8. Spazzolini C, Mullally J, Moss AJ, et al. Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. J Am Coll Cardiol 2009; 54:832-837.
9. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999; 99:529-533. (Pubitemid 29061868)
10. Napolitano C, Priori SG, Schwartz PJ, et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA 2005; 294:2975-2980. (Pubitemid 41817658)
11. Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol 2011; 57:51-59.
12. Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996; 12:17-23. (Pubitemid 26011314)
13. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80:795-803.
14. Wang Q, Shen J, Li Z, et al. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Mol Genet 1995; 4:1603-1607.
15. Mohler PJ, Schott JJ, Gramolini AO, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003; 421:634-639. (Pubitemid 36227671)
16. Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000; 102:1178-1185.
17. Plaster NM, Tawil R, Tristani-Firouzi M, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001; 105:511-519. (Pubitemid 32520856)
18. Splawski I, Timothy KW, Sharpe LM, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004; 119:19-31. (Pubitemid 39349317)
19. Vatta M, Ackerman MJ, Ye B, et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 2006; 114:2104-2112. (Pubitemid 44747890)
20. Chen L, Marquardt ML, Tester DJ, et al. Mutation of an A-kinase-anchoring protein causes long-QT syndrome. Proc Natl Acad Sci USA 2007; 104: 20990-20995.
21. Ueda K, Valdivia C, Medeiros-Domingo A, et al. Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex. Proc Natl Acad Sci USA 2008; 105: 9355-9360.
22. Yang Y, Yang Y, Liang B, et al. Identification of a Kir3.4 mutation in congenital long QT syndrome. Am J Hum Genet 2010; 86:872-880.
23. Medeiros-Domingo A, Kaku T, Tester DJ, et al. SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome. Circulation 2007; 116:134-142. (Pubitemid 47057518)
24. Moss AJ, Zareba W, Kaufman ES, et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-gogo- related gene potassium channel. Circulation 2002; 105:794-799. (Pubitemid 34174917)
25. Moss AJ, Shimizu W, Wilde AA, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation 2007; 115:2481-2489. (Pubitemid 46763221)
26. Migdalovich D, Moss AJ, Lopes CM, et al. Mutation and gender-specific risk in type 2 long QT syndrome: implications for risk stratification for lifethreatening cardiac events in patients with long QT syndrome. Heart Rhythm 2011; 8:1537-1543.
27. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011; 8:1308-1339.
28. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103:89-95. (Pubitemid 32050441)
29. Goldenberg I, Thottathil P, Lopes CM, et al. Trigger-specific ion-channel mechanisms, risk factors, and response to therapy in type 1 long QT syndrome. Heart Rhythm 2012; 9:49-56.
30. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348:1866-1874. (Pubitemid 36532312)
31. Liu JF, Jons C, Moss AJ, et al. Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with long QT syndrome. J Am Coll Cardiol 2011; 57:941-950.
32. Zareba W, Moss AJ, Locati EH, et al. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol 2003; 42:103-109. (Pubitemid 36760769)
33. Seth R, Moss AJ, McNitt S, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol 2007; 49:1092-1098. (Pubitemid 46349501)
34. Buber J, Mathew J, Moss AJ, et al. Risk of recurrent cardiac events after onset of menopause in women with congenital long-QT syndrome types 1 and 2. Circulation 2011; 123:2784-2791.
35. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na channel blockade and to increases in heart rate. Implications for genespecific therapy. Circulation 1995; 92:3381-3386.
36. Ruan Y, Liu N, Bloise R, et al. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 2007; 116:1137-1144. (Pubitemid 47360216)
37. Ruan Y, Denegri M, Liu N, et al. Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3. Circ Res 106:1374-1383.
38. Carvajal-Vergara X, Sevilla A, D'Souza SL, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010; 465:808-812.
39. Lahti AL, Kujala VJ, Chapman H, et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Models Mech 2011. [Epub ahead of print]
40. Malan D, Friedrichs S, Fleischmann BK, Sasse P. Cardiomyocytes obtained from induced pluripotent stem cells with long-QT syndrome 3 recapitulate typical disease-specific features in vitro. Circ Res 2011; 109:841-847.
41. Yazawa M, Hsueh B, Jia X, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011; 471: 230-234.
42. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111:659-670.
43. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000; 101:510-515. (Pubitemid 30080865)
44. Di Diego JM, Fish JM, Antzelevitch C. Brugada syndrome and ischemiainduced ST-segment elevation. Similarities and differences. J Electrocardiol 2005; 38 (4 Suppl.):14-17. (Pubitemid 41436481)
45. Probst V, Denjoy I, Meregalli PG, et al. Clinical aspects and prognosis of Brugada syndrome in children. Circulation 2007; 115:2042-2048. (Pubitemid 46625955)
46. Fowler SJ, Priori SG. Clinical spectrum of patients with a Brugada ECG. Curr Opin Cardiol 2009; 24:74-81.
47. Chen Q, Kirsch GE, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392:293-296. (Pubitemid 28155103)
48. London B, Michalec M, Mehdi H, et al. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na current and causes inherited arrhythmias. Circulation 2007; 116:2260-2268. (Pubitemid 350100331)
49. Watanabe H, Koopmann TT, Le Scouarnec S, et al. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest 2008; 118:2260-2268. (Pubitemid 351872343)
50. Hu D, Barajas-Martinez H, Burashnikov E, et al. A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet 2009; 2:270-278.
51. Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115:442-449. (Pubitemid 46184195)
52. Burashnikov E, Pfeiffer R, Barajas-Martinez H, et al. Mutations in the cardiac L-type calcium channel associated with inherited J wave syndromes and sudden cardiac death. Heart Rhythm 2010; 7:1872-1882.
53. Delpon E, Cordeiro JM, Nunez L, et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol 2008; 1:209-218.
54. Kattygnarath D, Maugenre S, Neyroud N, et al. MOG1: a new susceptibility gene for Brugada syndrome. Circ Cardiovasc Genet 2011; 4:261-268.
55. Medeiros-Domingo A, Tan BH, Crotti L, et al. Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes. Heart Rhythm 2010; 7:1466-1471.
56. Giudicessi JR, Ye D, Tester DJ, et al. Transient outward current (I(to)) gain-offunction mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm 2011; 8:1024-1032.
57. Smits JP, Eckardt L, Probst V, et al. Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5Arelated patients from non-SCN5A-related patients. J Am Coll Cardiol 2002; 40:350-356. (Pubitemid 34756299)
58. Meregalli PG, Tan HL, Probst V, et al. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm 2009; 6:341-348.
59. Alings M, Dekker L, Sadee A, Wilde A. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol 2001; 24 (9 Pt 1):1420-1422. (Pubitemid 32881972)
60. Hermida JS, Denjoy I, Clerc J, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 2004; 43:1853-1860. (Pubitemid 38622526)
61. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002; 105:1342-1347. (Pubitemid 34260426)
62. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003; 108:3092-3096. (Pubitemid 38031797)
63. Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada Syndrome Registry. Circulation 2010; 121:635-643. a role in risk stratification.
64. Priori SG, Gasparini M, Napolitano C, et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol 2012; 59: 37-45.
65. Gasparini M, Lunati M, Galimberti P, et al. Images in cardiovascular medicine. Endocardial implantation of a cardioverter-defibrillator in a 13-month-old child affected by long-QT syndrome and syndactyly. Circulation 2004; 110:e525-e527.
66. Brugada P, Brugada R, Mont L, et al. Natural history of Brugada syndrome: the prognostic value of programmed electrical stimulation of the heart. J Cardiovasc Electrophysiol 2003; 14:455-457. (Pubitemid 36583902)
67. Eckardt L, Kirchhof P, Schulze-Bahr E, et al. Electrophysiologic investigation in Brugada syndrome; yield of programmed ventricular stimulation at two ventricular sites with up to three premature beats. Eur Heart J 2002; 23:1394-1401. (Pubitemid 35407621)
68. Delise P, Allocca G, Marras E, et al. Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach. Eur Heart J 2011; 32:169-176.
69. Gasparini M, Priori SG, Mantica M, et al. Programmed electrical stimulation in Brugada syndrome: how reproducible are the results? J Cardiovasc Electrophysiol 2002 13 880-887.
70. Morita H, Kusano KF, Miura D, et al. Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. Circulation 2008; 118:1697-1704.
71. Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval: a new clinical syndrome? Cardiology 2000 94 99-102. (Pubitemid 32110328)
72. Maury P, Extramiana F, Sbragia P, et al. Short QT syndrome. Update on a recent entity. Arch Cardiovasc Dis 2008; 101:779-786.
73. Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol 2011; 58:587-595.
74. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol 2004; 43:1494-1499. (Pubitemid 38496360)
75. Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004; 109: 30-35. (Pubitemid 38056017)
76. Bellocq C, vanGinneken AC, Bezzina CR, et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 2004; 109:2394-2397. (Pubitemid 38679556)
77. Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 2005; 96:800-807. (Pubitemid 40559520)
78. Templin C, Ghadri JR, Rougier JS, et al. Identification of a novel loss-offunction calcium channel gene mutation in short QT syndrome (SQTS6). Eur Heart J 2011; 32:1077-1088.
79. Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995; 91:1512-1519.
80. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106:69-74. (Pubitemid 34747444)
81. Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 2009; 119:2426-2434.
82. Coumel P, Fidelle J, Lucet V, et al. Catecholamine-induced severe ventricular arrhythmias with Adam-Stokes in children: report of four cases. Br Heart J 1978; 40 (Suppl.):28-37.
83. Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001; 103:196-200. (Pubitemid 32095402)
84. Lahat H, Pras E, Olender T, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamineinduced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001; 69:1378-1384. (Pubitemid 33124218)
85. Cerrone M, DeGiuli L, Bloise R, et al. Value of entire open reading fraame screening of RyR2. Evidence from the Italian CPVT Registry. Heart Rhythm 2011; 8 (5 Suppl.):S462.
86. Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, et al. The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. J Am Coll Cardiol 2009; 54:2065-2074.
87. Tester DJ, Arya P, Will M, et al. Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing. Heart Rhythm 2006; 3:800-805. (Pubitemid 43960545)
88. Ruan Y, Boveri L, Rossenbacker T, et al. Arrhythmogenesis in mutant KCNJ2 associated catecholaminergic polymorphic ventricular tachycardia. Circulation 2008; 118:S525.
89. Mohler PJ, Splawski I, Napolitano C, et al. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc Natl Acad Sci USA 2004; 101:9137-9142. (Pubitemid 38781624)
90. Wehrens XH, Lehnart SE, Huang F, et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exerciseinduced sudden cardiac death. Cell 2003; 113:829-840. (Pubitemid 36792028)
91. Jiang D, Chen W, Xiao J, et al. Reduced threshold for luminal Ca2 activation of RyR1 underlies a causal mechanism of porcine malignant hyperthermia. J Biol Chem 2008; 283:20813-20820.
92. Jiang D, Wang R, Xiao B, et al. Enhanced store overload-induced Ca2 release and channel sensitivity to luminal Ca2 activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ Res 2005; 97:1173-1181.
93. Jiang D, Xiao B, Yang D, et al. RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overloadinduced Ca2 release (SOICR). Proc Natl Acad Sci USA 2004; 101: 13062-13067. (Pubitemid 39167583)
94. Cerrone M, Colombi B, Santoro M, et al. Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. Circ Res 2005; 96:e77-e82.
95. Cerrone M, Noujaim SF, Tolkacheva EG, et al. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res 2007; 101:1039-1048. (Pubitemid 350084981)
96. Liu N, Colombi B, Memmi M, et al. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ Res 2006; 99:292-298. (Pubitemid 44174937)
97. Liu N, Colombi B, Napolitano C, Priori S. Ca2/calmodulin kinase II inhibitor abolishes and prevents triggered activity in myocytes from RyR2R4496C/- knock-in mice. Heart Rhythm 2007; 4 (Suppl):S107-S108.
98. Knollmann BC, Chopra N, Hlaing T, et al. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2 release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 2006; 116:2510-2520. (Pubitemid 44330150)
99. Terentyev D, Viatchenko-Karpinski S, Gyorke I, et al. Calsequestrin determines the functional size and stability of cardiac intracellular calcium stores: Mechanism for hereditary arrhythmia. Proc Natl Acad Sci USA 2003; 100:11759-11764. (Pubitemid 37206008)
100. Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009; 15:380-383.
101. Liu N, Denegri M, Ruan Y, et al. Short Communication: Flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. Circ Res 2011; 109:291-295.
102. Van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 2011; 57:2244-2254.